Literature DB >> 20237878

Generic substitution: a potential risk factor for medication errors in hospitals.

Helle Håkonsen1, Heidi Skjønhaug Hopen, Linda Abelsen, Bjørg Ek, Else-Lydia Toverud.   

Abstract

INTRODUCTION: Efforts to restrain pharmaceutical costs in the Norwegian hospital sector have focused on putting pharmaceuticals out to tender with resultant frequent changes in medicine inventories. Due to the extent of physicians failing to prescribe from the hospital drug list, the nurses have to perform generic substitution on the wards. The objective of the present study is to investigate the hospital nurses' experiences with generic substitution and to explore their views on this strategy as a risk factor for medication errors.
METHODS: Personal interviews with 100 nurses who were employed in a large Norwegian hospital were conducted using a semistructured questionnaire.
RESULTS: In all, 75% of nurses thought it was problematic that the hospital's drug inventory was subject to frequent changes, and 91% believed that the high number of generic products may contribute to erroneous dispensing. Nevertheless, three out of four admitted that they seldom or never verified the feasibility of the substitution with the physician, and that it was seldom documented in the medical charts. In total, 42% of the nurses had experienced mistakes that occurred as a result of substitution. They claimed that the medication errors relating to generic substitution derived from difficult drug names, frequent changes in the drug inventory, and the increasing number of generic drugs, as well as from heavy workload and insufficient training.
CONCLUSIONS: The present study shows that generic substitution is often carried out by nurses on the wards. The nurses feel insecure about the situation and report that they do not have the necessary training for the task. They clearly believe that a high number of generic drugs and frequent generic substitutions are risk factors for medication errors. Hence, hospital managers should be aware that such strategies to reduce costs may interfere with patient safety.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20237878     DOI: 10.1007/s12325-010-0007-8

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  6 in total

1.  Opportunities for changes in the drug product design to enhance medication safety in older people: Evaluation of a national public portal for medication incidents.

Authors:  Fatma Karapinar-Çarkit; Patricia M L A van den Bemt; Mariam Sadik; Brigit van Soest; Wilma Knol; Florence van Hunsel; Diana A van Riet-Nales
Journal:  Br J Clin Pharmacol       Date:  2020-06-24       Impact factor: 4.335

2.  Complexity of Drug Substitutions Caused by Drug Tenders: A Mixed-Methods Study in Denmark.

Authors:  Lina Klitgaard Larsen; Emilie Middelbo Outzen; Parisa Gazerani; Hanne Plet
Journal:  Hosp Pharm       Date:  2019-12-21

3.  Special challenges for drug adherence following generic substitution in Pakistani immigrants living in Norway.

Authors:  Helle Håkonsen; Else-Lydia Toverud
Journal:  Eur J Clin Pharmacol       Date:  2010-12-16       Impact factor: 2.953

4.  Norwegian patients on generic antihypertensive drugs: a qualitative study of their own experiences.

Authors:  Else-Lydia Toverud; Anne Kjersti Røise; Grete Hogstad; Inger Wabø
Journal:  Eur J Clin Pharmacol       Date:  2010-11-23       Impact factor: 2.953

Review 5.  A Systematic Review of Physicians' and Pharmacists' Perspectives on Generic Drug Use: What are the Global Challenges?

Authors:  Else-Lydia Toverud; Katrin Hartmann; Helle Håkonsen
Journal:  Appl Health Econ Health Policy       Date:  2015-08       Impact factor: 2.561

6.  Drug change: 'a hassle like no other'. An in-depth investigation using the Danish patient safety database and focus group interviews with Danish hospital personnel.

Authors:  Joo Hanne Poulsen; Rikke Mie Rishøj; Hanne Fischer; Trine Kart; Lotte Stig Nørgaard; Christian Sevel; Peter Dieckmann; Marianne Hald Clemmensen
Journal:  Ther Adv Drug Saf       Date:  2019-07-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.